IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ication of LIEPKALNS ET AL. Examiner:

KAM, CHIH

JUN 11 5005

Application No.: 09/595,947

COPY OF PAPERS ORIGINALLY FILED Art Unit:

1653

TECH CENTER 1600/291

Filed:

JUNE 16, 2000

Title:

POLYPEPTIDES OF THE "BASIC-

HELIX-LOOP-HELIX" bHLH FAMILY, CORRESPONDING NUCLEIC ACID SEQUENCES I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE COPIES PURSUANT TO 37 C.F.R. 1.821 (f)

Commissioner for Patents

Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. i.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

hiam C. Coppola, Re

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, New Jersey 08807-0800

Telephone (908) 231-4854

Telefax

(908) 231-2626

Aventis Docket No. ST96042AUS





UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/595,947	06/16/2000	Christine Icard-	•	ST96042 AUS.	2918	
5487 7	590 05/02/2002					
AVENTIS PHARMACEUTICALS, INC. PATENTS DEPARTMENT ROUTE 202-206, P.O. BOX 6800 BRIDGEWATER, NJ 08807-0800			20	EXAMINER		
PATENTS DE ROUTE 202-2	PARTMENT 06, P.O. BOX 6800	99 A	107773	KAM, CHIH MIN		
	ER, NJ 08807-0800	To the state of th	`&\		B. OFFI VIII (PER	
		\B	6	ART UNIT	PAPER NUMBER	
		S MAY 20	102 5	DATE MAILED: 05/02/2002	9	
		୍ଷ୍ଟି କଥାଞ୍ଚମt D	ept.	DATE MAILED. 03/02/2002	·	
		182	A G		.ED	
		Se Se Sent Con	12/200		TO BECEIVED	
Please find below and/or attached an Office communication concerning this application or professing.						
11 200						
COPY OF PAPERS					2018 200 18	
			GINALLY FILED	CLI CENTER 100		
			-		TECH CENTER 160012	
Prepare Reply To 2nd Seg. Regnits - 5/13/62 Reply To Sequence Regnito - 6/2/02						
Reply To Sequence Reamto - 10/2/02						
		•	2 1	(n. +'/	Dealline - 11/2/02	
	A(CTION DUE	Riply To	Seg, Regin 15/1	Deadline - 11/2/02	
			4			
	חו	JE DATE	1			
			^	-1-1-	-	
	וטן	KTD BY	- Jb	519102	⇒	
	A	TY	_ le	icc		





UNITED STATES DEPARTMENT OF COMMERCE Patent and Tradem Office

Address: ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

APPLICATION NO.1
CONTROL NO.

FILING DATE

FIRST NAMED INVENTOR / PATENT IN REEXAMINATION

ATTORNEY DOCKET NO.

COPY OF PAPERS ORIGINALLY FILED **EXAMINER**

ART UNIT

PAPER

9 RECEIVED

DATE MAILED:

JUN 1 1 2002

TECH CENTER 1600/2900

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

The communication filed November 15, 2001 is not fully responsive to the Office communication mailed September 28, 2001 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules or CRF Diskette Problem Report. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Since the above-mentioned reply appears to be bona fide attempt to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), applicant is given a TIME PERIOD of ONE (1) MONTH from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821(g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (703) 308-9437. The examiner can normally be reached on 8:00-4:30 from Monday to Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, can be reached on (703) 308-2923. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-0294. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

A reply to a notice to comply with the sequence rules should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office.

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Bio (httm, EFS Submission User Manual - ePAVE)

2. Mailed to:

U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

- 3. Mailed by Federal Express, United Parcel Service or other delivery service to:
- U. S. Patent and Trademark Office

2011 South Clark Place

Customer Window, Box Sequence Crystal Plaza Two, Lobby, Room 1B03 Arlington, Virginia 22202



4. Hand Carried directly to the Customer Window at: 2011 South Clark Place
Crystal Plaza Two, Lobby, Room 1B03, Box Sequence, Arlington, Virginia 22202

Chih-Min Kam, Ph.D. May 1, 2002 CHK

Chris behans I for Christopher B. F. Low Superansony patent enaumer Technology center 1000